Sun Pharma to acquire Checkpoint Therapeutics for $355 million in cash and milestone payments

The upfront cash payment of $4.1 per share of common stock represents a premium of approximately 66% to Checkpoint’s last closing price.

Leave a Reply

Your email address will not be published. Required fields are marked *